Theodore Laetsch
Children's Hospital of Philadelphia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Theodore Laetsch as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06458036 · Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)Children's Hospital of Philadelphia · recruiting · Differentiated Thyroid Cancer, Pediatric Cancer, Cancer · principal investigator
- Ph1NCT06156410 · Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasChildren's Hospital of Philadelphia · recruiting · Ewing Sarcoma, Osteosarcoma, Sarcomas · principal investigator
- Ph1/Ph2NCT05918640 · Lurbinectedin in FET-Fused TumorsChildren's Hospital of Philadelphia · recruiting · Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer · principal investigator
- N/ANCT05910307 · Synovial Sarcoma Registry / Biospecimen RepositoryChildren's Hospital of Philadelphia · recruiting · Synovial Sarcoma · principal investigator
- Ph2NCT05783323 · Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid CancerChildren's Hospital of Philadelphia · recruiting · Differentiated Thyroid Cancer, Pediatric Cancer, Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- PROMISE — Pediatric Rare-tumor Observational MultI-Source Evidence NetworkU01FD008977 · FDA · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2026 · $1,498,821 awarded in 2026Same name and institution; not confirmed by an ID
- Rare Tumor Clinical Research SpecialistR50CA305079 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2025 to 2026 · $197,518 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in osteosarcoma, ranked by citations from NIH iCite, fetched 2026-11-12 09:14 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.Clin Cancer Res · 202216 citationsRCR 1.2
- Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D.JCO Precis Oncol · 20247 citationsRCR 1.0
- A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.Pediatr Blood Cancer · 20251 citationsRCR 0.1
- Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors.Pediatr Blood Cancer · 20251 citationsRCR 0.4